Literature DB >> 17151331

Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study.

Ian H de Boer1, Shalamar D Sibley, Bryan Kestenbaum, Joshua N Sampson, Bessie Young, Patricia A Cleary, Michael W Steffes, Noel S Weiss, John D Brunzell.   

Abstract

Weight gain and central obesity are associated with insulin resistance, hypertension, and dyslipidemia in type 1 diabetes. These metabolic abnormalities are risk factors for kidney disease in the general population, but data addressing the relationship of central obesity with kidney disease in type 1 diabetes are limited. Whether waist circumference is associated with incident microalbuminuria and change in creatinine clearance was examined among 1279 participants who had type 1 diabetes and were enrolled in the Epidemiology of Diabetes Interventions and Complications Study, the observational extension of the Diabetes Control and Complications Trial (DCCT). Ninety-three of 1105 participants with normal albumin excretion rate (AER) at DCCT closeout developed incident microalbuminuria over 5.8 yr of follow-up. The hazard ratio for incident microalbuminuria that was associated with each 10-cm greater waist circumference at DCCT closeout was 1.34 (95% confidence interval 1.07 to 1.68), after adjustment for DCCT closeout age, gender, duration of diabetes, treatment group, smoking status, glycosylated hemoglobin, and AER. This increased risk was modestly attenuated when additional adjustment was made for levels of BP and serum lipids. Creatinine clearance declined by an average of 0.34 ml/min per 1.73 m2 each yr over 8 yr of follow-up. Greater rate of decline in creatinine clearance was associated with greater age, conventional insulin therapy during the DCCT, smoking, and greater glycosylated hemoglobin and AER at DCCT closeout but not with waist circumference. In conclusion, waist circumference predicts the subsequent development of microalbuminuria in type 1 diabetes. In contrast, no association of waist circumference with decline in creatinine clearance was observed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151331      PMCID: PMC2622719          DOI: 10.1681/ASN.2006040394

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue.

Authors:  S Lemieux; D Prud'homme; C Bouchard; A Tremblay; J P Després
Journal:  Am J Clin Nutr       Date:  1996-11       Impact factor: 7.045

3.  Visceral fat and cardiovascular risk factors in Chinese NIDDM patients.

Authors:  P J Anderson; J C Chan; Y L Chan; B Tomlinson; R P Young; Z S Lee; K K Lee; C Metreweli; C S Cockram; J A Critchley
Journal:  Diabetes Care       Date:  1997-12       Impact factor: 19.112

4.  Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.

Authors:  S D Sibley; J E Hokanson; M W Steffes; J Q Purnell; S M Marcovina; P A Cleary; J D Brunzell
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

5.  The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients.

Authors:  Julia M Steinke; Alan R Sinaiko; Michael S Kramer; Samy Suissa; Blanche M Chavers; Michael Mauer
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

6.  Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group.

Authors: 
Journal:  Kidney Int       Date:  1995-06       Impact factor: 10.612

7.  Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group.

Authors:  A S Levey; T Greene; M D Schluchter; P A Cleary; P E Teschan; R A Lorenz; M E Molitch; W E Mitch; C Siebert; P M Hall
Journal:  J Am Soc Nephrol       Date:  1993-11       Impact factor: 10.121

8.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  The association of waist/hip ratio with diabetes complications in an adult IDDM population.

Authors:  W L Stuhldreher; D J Becker; A L Drash; D Ellis; L H Kuller; S K Wolfson; T J Orchard
Journal:  J Clin Epidemiol       Date:  1994-05       Impact factor: 6.437

10.  Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.

Authors:  J Q Purnell; J E Hokanson; S M Marcovina; M W Steffes; P A Cleary; J D Brunzell
Journal:  JAMA       Date:  1998-07-08       Impact factor: 157.335

View more
  52 in total

1.  Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.

Authors:  Ahmed A Elmarakby; Jessica Faulkner; Mohammed Al-Shabrawey; Mong-Heng Wang; Krishna Rao Maddipati; John D Imig
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-10       Impact factor: 3.619

2.  Association of subcutaneous and visceral adiposity with albuminuria: the Framingham Heart Study.

Authors:  Meredith C Foster; Shih-Jen Hwang; Joseph M Massaro; Udo Hoffmann; Ian H DeBoer; Sander J Robins; Ramachandran S Vasan; Caroline S Fox
Journal:  Obesity (Silver Spring)       Date:  2010-12-23       Impact factor: 5.002

Review 3.  Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.

Authors:  Rikki M Tanner; Todd M Brown; Paul Muntner
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

4.  Intra-abdominal fat and elevated urine albumin excretion in men with type 1 diabetes.

Authors:  Shalamar D Sibley; Ian H de Boer; Michael W Steffes; John D Brunzell
Journal:  Diabetes Care       Date:  2007-04-24       Impact factor: 19.112

5.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

6.  Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus.

Authors:  Ian H de Boer; Bryan Kestenbaum; Tessa C Rue; Michael W Steffes; Patricia A Cleary; Mark E Molitch; John M Lachin; Noel S Weiss; John D Brunzell
Journal:  Arch Intern Med       Date:  2008-09-22

7.  Lifestyle factors and indices of kidney function in the Framingham Heart Study.

Authors:  Meredith C Foster; Shih-Jen Hwang; Joseph M Massaro; Paul F Jacques; Caroline S Fox; Audrey Y Chu
Journal:  Am J Nephrol       Date:  2015-05-20       Impact factor: 3.754

8.  Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia.

Authors:  Ahmed Bettaieb; Shinichiro Koike; Ming-Fo Hsu; Yoshihiro Ito; Samah Chahed; Santana Bachaalany; Artiom Gruzdev; Miguel Calvo-Rubio; Kin Sing Stephen Lee; Bora Inceoglu; John D Imig; Jose M Villalba; Darryl C Zeldin; Bruce D Hammock; Fawaz G Haj
Journal:  Biochim Biophys Acta Gen Subj       Date:  2017-07-27       Impact factor: 3.770

9.  Obesity and change in estimated GFR among older adults.

Authors:  Ian H de Boer; Ronit Katz; Linda F Fried; Joachim H Ix; Jose Luchsinger; Mark J Sarnak; Michael G Shlipak; David S Siscovick; Bryan Kestenbaum
Journal:  Am J Kidney Dis       Date:  2009-09-25       Impact factor: 8.860

10.  Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension.

Authors:  Martin Thoenes; Jan-Christian Reil; Bobby Varkey Khan; Peter Bramlage; Massimo Volpe; Wilhelm Kirch; Michael Böhm
Journal:  Vasc Health Risk Manag       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.